The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

被引：0
|
作者：
Panaccione, R. [1 ]
Sapin, C. [2 ]
Chan-Diehl, F. W. [3 ]
Moses, R. E. [3 ]
Siegmund, B. [4 ]
Walsh, A. [5 ]
Kobayashi, T. [6 ]
Parambir, D. S. [7 ]
Travis, S. [8 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Fac Med, Calgary, AB, Canada
[2] Eli Lilly France, Rheumatol Gastroenterol Real World Access Analyt, Neuilly Sur Seine, France
[3] Eli Lilly & Co, Gastroenterol, Indianapolis, IN USA
[4] Univ Med Berlin, Medizin Klin Gastroenterol Infektiol, Rheumatol Charite, Berlin, Germany
[5] Nuffield Hlth Manor Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan
[7] Northwestern Univ, Gastroenterol & Hepatol, Feinberg Sch Med, Chicago, IL USA
[8] Univ Oxford, Nuffield Dept Med, Oxford, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP90
引用
收藏
页码：I167 / I168
页数：2
相关论文
共 50 条
  • [1] Association of Faecal Calprotectin With Symptomatic, Endoscopic, and Clinical Remission in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
    Vermeire, Severine
    Long, Millie D.
    Dulai, Parambir S.
    Ma, Christopher
    Chan-diehl, Faye
    Moses, Richard
    Zhu, Baojin
    Paulissen, Jerome
    Travis, Simon
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S958 - S958
  • [2] The Effect of Mirikizumab on Fecal Calprotectin and C-Reactive Protein in Phase 3 Studies of Patients With Moderately-to-Severely Active Ulcerative Colitis
    Siegmund, Britta
    Sands, Bruce E.
    Samaan, Karen
    Li, Xingyuan
    Morris, Nathan
    Gibble, Theresa Hunter
    Redondo, Isabel
    Lissoos, Trevor
    D'Haens, Geert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S543 - S544
  • [3] Endoscopic and Histologic Remission After 2 Years Treatment With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Margo, Fernando
    Peyrin-Biroulet, Laurent
    Kobayashi, Taku
    Jairath, Vipul
    Walsh, Alissa
    Christensen, Britt
    Wu, Jianmin
    Park, Gina
    Redondo, Isabel
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S812
  • [4] Decrease in fecal calprotectin and C-reactive protein levels correlate with improved clinical outcomes in patients with moderately to severely active Crohn's disease treated with mirikizumab
    Charabaty, A.
    Kayal, M.
    Kelly, C. R.
    Cohen, B. L.
    D'Haens, G.
    Hart, A.
    Chan-Diehl, F.
    Yu, G.
    Brogan, Y.
    Protic, M.
    Moses, R.
    Fisher, D.
    Travis, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1628 - i1630
  • [5] Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis
    Hahn, G. Drugg
    Flores, C.
    Afif, W.
    Wild, G.
    Bitton, A.
    Lakatos, P. L.
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I843 - I844
  • [6] Faecal calprotectin in assessing endoscopic and histologic remission in patients with ulcerative colitis
    Mak, W. Y.
    Buisson, A.
    Andersen, M. J., Jr.
    Lei, D.
    Pekow, J.
    Cohen, R. D.
    Kahn, S. A.
    Pereira, B.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S199 - S200
  • [7] EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
    D'Haens, Geert
    Higgins, Peter D.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard
    Redondo, Isabel
    Escobar, Rodrigo
    Morris, Nathan
    Kobayashi, Taku
    GASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1086
  • [8] Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
    D'Haens, G.
    Higgins, P. D. R.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Lee, S.
    Moses, R. E.
    Redondo, I.
    Escobar, R.
    Morris, N.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 682 - 682
  • [9] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Pai, Rish
    Canavan, James
    Tuttle, Jay
    Durante, Michael
    Arora, Vipin
    Milch, Catherine
    Harpaz, Noam
    D'Haens, Geert R.
    Sands, Bruce E.
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1187 - S1187
  • [10] Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial
    Yarur, Andres J.
    Chiorean, Michael, V
    Panes, Julian
    Jairath, Vipul
    Zhang, Jinkun
    Rabbat, Christopher J.
    Sandborn, William J.
    Vermeire, Severine
    Peyrin-Biroulet, Laurent
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (06): : 885 - 894
12345